Skip to content
Review

The Biphasic Role of Reactive Oxygen Species in Ovarian Cancer Progression and Therapeutics: Crosstalk Among Metabolism, Ferroptosis, and the Tumor Immune Microenvironment.

Aug 2026 · Critical reviews in oncology/hematology · Vol 227, pp. 105542 · 0 citations · 102 references
Medicine

TL;DR

A dynamic ROS modulation framework is proposed that advocates for precise, personalized pro-oxidant or antioxidant interventions based on each patient's tumor subtype, real-time redox state, and TIME characteristics, offering a robust translational path for next-generation precision oncology in OC.

Abstract

Ovarian cancer (OC) is one of the most lethal malignancies of the female reproductive system, and its frequent recurrence and treatment resistance are major obstacles to improving patient outcomes. Studies indicate that the progression and treatment resistance of OC are driven by substantial metabolic and mitochondrial reprogramming. As key byproducts and signaling molecules of mitochondrial metabolism, reactive oxygen species (ROS) have emerged as a central regulatory node in both OC progression and treatment response. While tumor cells enhance their redox-buffering capacity to maintain survival, a trait that exhibits high heterogeneity across histologic subtypes, ROS ultimately exert a biphasic effect determined by dose, spatiotemporal dynamics, and cellular state. On the one hand, a chronic low-to-moderate oxidative burden sustains redox-sensitive prosurvival signaling and drives tumor proliferation, angiogenesis, and invasion. This is primarily achieved by activating antioxidant pathways, such as the nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which mediates resistance to platinum-based chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. On the other hand, an acute surge in oxidative stress that breaches the cellular antioxidant-buffering threshold triggers regulated cell death, primarily through the intrinsic mitochondrial apoptotic pathway and iron-dependent lipid peroxidation (ferroptosis). Crucially, ROS-induced ferroptosis and metabolic shifts do not occur in isolation; they actively participate in extensive crosstalk with the tumor immune microenvironment (TIME). Given this complex biology, targeting redox balance represents a highly promising therapeutic strategy. Interventions include scavenging ROS to block prosurvival signaling, or employing specific drugs and nanodelivery systems to amplify oxidative stress to lethal levels. When rationally combined with immunotherapies, these ROS-modulating strategies can effectively reverse tumor resistance by remodeling the TIME. This review systematically summarizes the biological properties of ROS, the mechanisms of metabolic and mitochondrial reprogramming across OC histologic subtypes, and the dual protumor and antitumor roles of ROS, with particular emphasis on the interplay between ferroptosis and immune regulation. Furthermore, we highlight emerging pro-oxidant therapies, ferroptosis inducers, nanodelivery systems, and immune-based combinatorial strategies. Ultimately, we propose a dynamic ROS modulation framework that advocates for precise, personalized pro-oxidant or antioxidant interventions based on each patient's tumor subtype, real-time redox state, and TIME characteristics, offering a robust translational path for next-generation precision oncology in OC.

View source

Similar papers

Review Open access Sep 2026

Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications

The potential of understanding oxidative stress mechanisms to develop therapeutic strategies that target redox balance and homeostasis, aiming to overcome resistance and improve survival outcomes for glioblastoma patients is discussed.

Salma Lamrabet, A. Houssaini, Sanae Bennis et al. · 0 citations
Review Open access Sep 2026

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges. Reactive oxygen species (ROS) play a dual role in br...

Marija Nikolovska, R. Stojchevski, A. Eftimov et al. · 0 citations
Review Open access Aug 2026

Oxidative stress and cancer: current insights and therapeutic implications

Oxidative stress good or evil? Oxidative stress occurs when the balance between reactive oxygen species (ROS) and antioxidant defenses shifts toward an excess of ROS; while essential in physiological processes, it plays a context-dependent role in cancer, contributing to both the promotion and inhibition of tumorigenes...

María Escribano-Cebrián, M. Bataller, M. Biasini et al. · 0 citations
Review Aug 2026

Melatonin in lung cancer: integrating molecular mechanisms, tumor microenvironment regulation, apoptotic signaling, and therapeutic opportunities.

Melatonin (MLT), an endogenous indoleamine involved in circadian regulation, has emerged as a potential anticancer molecule due to its pleiotropic effects on tumor biology, and emerging evidence suggests that MLT may enhance the sensitivity of LC cells to conventional therapies through modulation of cellular stress res...

Jun Wu, Hong-Mei Kang, Yu Huang et al. · 0 citations
Review Open access Sep 2026

Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progression and Resistance Through Supplement Therapy

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies worldwide because of delayed diagnosis, rapid metastatic progression, profound immune suppression, and limited therapeutic responsiveness. The pancreatic tumor microenvironment is characterized by severe hypoxia, stromal desmoplasia, meta...

Sara Fanijavadi, L. H. Jensen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.